Biogen (BIIB) Intangibles (2009 - 2026)
Biogen (BIIB) posted quarterly Intangibles of $13.5 billion for Q2 2026, up 42.77% year-over-year from $9.5 billion in Q2 2025, and up 49.29% quarter-over-quarter from $9.1 billion in Q1 2026.
Biogen (BIIB) Intangibles (2009 - 2026) Analysis & Trends
Biogen's Intangibles history runs 18 years deep, the most recent figure standing at $13.5 billion for Q2 2026.
- In Q2 2026, Intangibles rose 42.77% year-over-year to $13.5 billion; the TTM figure through Jun 2026 stood at $13.5 billion (up 42.77% YoY), while the FY2025 annual figure was $9.2 billion, down 5.29% from the prior year.
- Intangibles for Q2 2026 stood at $13.5 billion, up from $9.1 billion in the prior quarter.
- The five-year high for Intangibles was $13.5 billion in Q2 2026, with the low at $1.8 billion in Q2 2023.
- The 5-year median for Intangibles is $8.3 billion (2024), against an average of $6.9 billion.
- Peak annual rise in Intangibles reached 489.26% in 2022, while the deepest fall reached 16.71% in 2022.
- Biogen's Intangibles stood at $1.9 billion in 2022, then jumped by 352.03% to $8.4 billion in 2023, then increased by 15.88% to $9.7 billion in 2024, then declined by 5.29% to $9.2 billion in 2025, then surged by 47.26% to $13.5 billion in 2026.
- Business Quant data shows BIIB's Intangibles at $13.5 billion in Q2 2026, $9.1 billion in Q1 2026, and $9.2 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 48.23 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 49.14 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 24.98 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 42.07 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 37.72 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 20.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 14.03 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 47.05 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 22.54 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 13.52 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.52 Bn |
| Mar 31, 2026 | 9.05 Bn |
| Dec 31, 2025 | 9.18 Bn |
| Sep 30, 2025 | 9.33 Bn |
| Jun 30, 2025 | 9.47 Bn |
| Mar 31, 2025 | 9.58 Bn |
| Dec 31, 2024 | 9.69 Bn |
| Sep 30, 2024 | 9.81 Bn |
| Jun 30, 2024 | 8.23 Bn |
| Mar 31, 2024 | 8.28 Bn |
| Dec 31, 2023 | 8.36 Bn |
| Sep 30, 2023 | 7.34 Bn |
| Jun 30, 2023 | 1.78 Bn |
| Mar 31, 2023 | 1.81 Bn |
| Dec 31, 2022 | 1.85 Bn |
| Sep 30, 2022 | 2.01 Bn |
| Jun 30, 2022 | 2.08 Bn |
| Mar 31, 2022 | 2.15 Bn |
| Dec 31, 2021 | 2.22 Bn |
| Sep 30, 2021 | 2.29 Bn |